Genzyme completes $345 million Bioenvision deal

CAMBRIDGE, Mass. Genzyme has completed its acquisition of Bioenvision, in a deal worth $345 million, when it was announced that shareholders controlling 56 percent of shares voted in favor of the deal.

With the acquisition, Genzyme gains exclusive rights to clofarabine, a drug for the treatment of adult acute myeloid leukemia.

According to Mark J. Enyedy, president of Genzyme Oncology, “We are deeply committed to furthering the clinical development of clofarabine and making it available on a global basis so that patients around the world with these very difficult forms of cancer will have access to the therapy. The successful completion of this acquisition creates the platform on which we will continue to build an international commercial presence for our oncology business.”